Article
Moxifloxacin gains FDA approval
Author(s):
Dallas-Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month review of the drug.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
